Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

159 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Association of a gene-expression subtype to outcome and treatment response in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab.
Serafini MS, Cavalieri S, Licitra L, Pistore F, Lenoci D, Canevari S, Airoldi M, Cossu Rocca M, Strojan P, Kuhar CG, Merlano M, Perrone F, Vingiani A, Denaro N, Perri F, Argiris A, Gurizzan C, Ghi MG, Cassano A, Allegrini G, Bossi P, De Cecco L. Serafini MS, et al. Among authors: argiris a. J Immunother Cancer. 2024 Jan 30;12(1):e007823. doi: 10.1136/jitc-2023-007823. J Immunother Cancer. 2024. PMID: 38290766 Free PMC article. Clinical Trial.
A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study.
Burtness BA, Manola J, Axelrod R, Argiris A, Forastiere AA; Eastern Cooperative Oncology Group. Burtness BA, et al. Among authors: argiris a. Ann Oncol. 2008 May;19(5):977-83. doi: 10.1093/annonc/mdm591. Epub 2008 Feb 21. Ann Oncol. 2008. PMID: 18296423 Free article. Clinical Trial.
The impact of tumor volume and radiotherapy dose on outcome in previously irradiated recurrent squamous cell carcinoma of the head and neck treated with stereotactic body radiation therapy.
Rwigema JC, Heron DE, Ferris RL, Andrade RS, Gibson MK, Yang Y, Ozhasoglu C, Argiris AE, Grandis JR, Burton SA. Rwigema JC, et al. Among authors: argiris ae. Am J Clin Oncol. 2011 Aug;34(4):372-9. doi: 10.1097/COC.0b013e3181e84dc0. Am J Clin Oncol. 2011. PMID: 20859194 Free PMC article.
A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303).
Argiris A, Ghebremichael M, Burtness B, Axelrod RS, Deconti RC, Forastiere AA. Argiris A, et al. Cancer. 2011 Aug 1;117(15):3374-82. doi: 10.1002/cncr.25852. Epub 2011 Jan 18. Cancer. 2011. PMID: 21246525 Free PMC article. Clinical Trial.
Tumor epidermal growth factor receptor and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma.
Wheeler S, Siwak DR, Chai R, LaValle C, Seethala RR, Wang L, Cieply K, Sherer C, Joy C, Mills GB, Argiris A, Siegfried JM, Grandis JR, Egloff AM. Wheeler S, et al. Among authors: argiris a. Clin Cancer Res. 2012 Apr 15;18(8):2278-89. doi: 10.1158/1078-0432.CCR-11-1593. Epub 2012 Feb 20. Clin Cancer Res. 2012. PMID: 22351687 Free PMC article.
159 results